Outcome of Critically Ill Patients with Testicular Cancer
Table 2
Characteristics of the patients according to the presence of hospital mortality.
Variable
Survivor ()
Nonsurvivor ()
Age, years, mean ± SD
0.271
APACHE II, point, mean ± SD
0.033
MEXSOFA, mean ± SD
<0.001
Primary histology, (%)
Nonseminomatous germ cell tumors
30 (93.7)
25 (89.2)
0.657
Seminomatous germ cell tumors
2 (6.2)
3 (10.7)
Metastasis, (%)
No
0 (0)
2 (7.1)
0.214
Yes
32 (100)
26 (92.8)
Sites of metastasis, (%)
Pulmonary
2 (6.2)
4 (15.3)
0.408
Extrapulmonary
11 (34.3)
6 (23)
Mixed
19 (59.3)
16 (61.5)
IGCCCG risk classification
Good
0 (0)
2 (7.1)
0.240
Intermediate
4 (12.5)
5 (17.8)
Poor
28 (87.5)
21 (75)
ECOG performance status, (%)
0–2
20 (62.5)
14 (50)
0.330
3-4
12 (37.5)
14 (50)
Tumor Marker, median (IQR)
-fetoprotein, µg/L
3.53 (2.19–27)
7.28 (2.0–336.5)
0.662
Human chorionic gonadotropin, U/L
0 (0–2.98)
12,189 (13–191,015)
<0.001
Lactate dehydrogenase, U/L
214 (155.5–361.5)
1,251 (465.5–2,361.5)
<0.001
Need for vasopressors, (%)
Yes
24 (75)
9 (32.1)
0.001
No
8 (25)
19 (67.8)
Need for IMV, (%)
Yes
19 (59.3)
24 (85.7)
0.024
No
13 (40.7)
4 (14.3)
Length of IMV, day
1 (0–4)
2.5 (1–8.5)
0.015
Length of stay in ICU, median, (IQR)
2.5 (2–5)
3 (1.5–8.5)
0.001
Length of stay in hospital wards before ICU admission, median (IQR)
1.5 (1–5)
1 (0–6)
<0.001
APACHE, Acute Physiology and Chronic Health Evaluation. ICU, intensive care unit. IGCCCG, International Germ Cell Cancer Collaborative Group. ECOG, Eastern Cooperative Oncology Group. IMV, invasive mechanical ventilation.
